From Weight-loss Jabs to Ongoing Covid Vaccine Vigilance - Qinecsa

From Weight-loss Jabs to Ongoing Covid Vaccine Vigilance

Why an AI Enhanced Approach to Pharmacovigilance Case Processing is now Non-negotiable

Qinecsa CEO, Adam Sherlock has been featured in Simedics (The Journal of mHealth) discussing the critical role of AI-enhanced adverse event case processing in pharmacovigilance.

In this article, Adam highlights how technology-driven approaches are vital to ensuring the safety and effectiveness of breakthrough treatments – from weight-loss therapies to ongoing COVID-19 vaccine monitoring. Now more than ever, AI is a game-changer in optimizing patient safety and regulatory compliance.

Read article

Recent Articles

The Productivity Crisis That Persists Even Now: What Will It Take to Free Up PV Professionals to Assess Safety, Rather Than Coordinate Data?

Embracing quantitative signal detection methods as a smaller MAH

Real-Time Safety Signals Drive Continuous PV Insight

From Complaint Handling to Active Surveillance

Continuous Safety Surveillance for Medical Devices

Are patient outcomes getting lost in safety data complexity?

Previous Press Release: Qinecsa Solutions announces acquisition of MyMeds&Me

Next Bridging the Gap to ROI: The Power of Technology Backed by Expertise